At today's event, Thermo Fisher Scientific highlighted:

• Attractive end markets that are fueled by enduring long-term trends
  • Thermo Fisher serves an attractive $255 billion market with improving demand trends and strong long-term growth fundamentals.
    
    
    
     
• Incredibly well-positioned industry leadership
  • Our industry-leading businesses enable our customers' success and benefit from the scale and depth of our combined capabilities.
    
    
    
     
• Proven growth strategy drives share gain
  • Innovation: Our cutting-edge technologies accelerate our customers' innovation and enhance their productivity.
  • Trusted Partner: Our expertise, scale, and depth of capabilities make us the partner of choice to solve customers' most important challenges.
  • Commercial engine: Our exceptional reach and depth of engagement create a competitive advantage.
    
    
    
     
• Practical Process Improvement Business System (PPI) enables outstanding execution
  • PPI is the core of Thermo Fisher's culture, with a focus on continuous improvement that drives quality, productivity and customer allegiance and engages every colleague to find a better way, every day.
    
    
    
     
• AI is a powerful accelerator for the company's future
  • AI will accelerate scientific breakthroughs and improve productivity and returns on drug discovery – fueling additional investment into our customers' drug pipelines and driving additional demand for our capabilities.
  • We are uniquely positioned to capture AI-driven growth through our presence across the full drug development value chain.
  • AI and automation are accelerating the impact of PPI across the company as we deploy the capabilities at scale.
    
    
    
     
• Disciplined approach to capital deployment creates tremendous value
  • A disciplined combination of strategic M&A and returning capital to shareholders enables us to further strengthen the company's industry leadership and creates significant value for our shareholders.
    
    
    
     
• Outstanding track record of financial performance and an exceptional long-term outlook
  • Thermo Fisher's proven growth strategy and disciplined approach to capital deployment position the company to deliver 7% organic revenue CAGR and low-teens adjusted EPS growth over the long term.